Clinical Evaluation of Fiducial Marker Pre-Planning for Virtual Bronchoscopic Navigation Implantation in Lung Tumour Patients Treated With CyberKnife.
CyberKnife
dose area product
fiducial marker
lung cancer
virtual bronchoscopic navigation
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
01
2022
accepted:
13
05
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
6
7
2022
Statut:
epublish
Résumé
For the treatment of invisible lung tumours with CyberKnife (CK), fiducial markers (FMs) were implanted as an internal surrogate under virtual bronchoscopic navigation (VBN). This research aims to study the benefits of introducing an additional procedure in assigning the optimal FM positions using a pre-procedure planning system and performing virtual simulation before implantation. The objectives were 1) to reduce the duration of the FM implantation procedure, 2) to reduce the radiation exposure in dose area product (DAP) (dGy*cm This study is retrospective, single-centre, and observational in nature. A total of 32 patients were divided into two groups. In Group 1, 18 patients underwent conventional VBN FM implantation. In Group 2, 14 patients underwent additional pre-procedure planning and simulation. The steps of pre-procedure planning include 1) importing CT images into the treatment planning system (Eclipse, Varian Medical Systems, Inc.) and delineating five to six FMs in their ideal virtual positions and 2) copying the FM configuration into VBN planning software (LungPoint Bronchus Medical, Inc.) for verification and simulation. Finally, the verified FMs were deployed through VBN with the guidance of the LungPoint planning software. A total of 162 FMs were implanted among 35 lesions in 32 patients aged from 37 to 92 (median = 66; 16 men and 16 women). Results showed that 1) the average FM insertion time was shortened from 41 min (SD = 2.05) to 23 min (SD = 1.25), p = 0.00; 2) the average absorbed dose of patients in DAP was decreased from 67.4 cGy*cm Pre-procedure planning reduces the FM implantation duration from 41.1 to 22.9 min, reduces the radiation exposure in DAP from 67.4 to 25.3 dGy*cm
Identifiants
pubmed: 35785178
doi: 10.3389/fonc.2022.860641
pmc: PMC9246503
doi:
Types de publication
Journal Article
Langues
eng
Pagination
860641Informations de copyright
Copyright © 2022 Ku, Lam, Wu, Chan, Chan, Cheng, Yuen and Cai.
Déclaration de conflit d'intérêts
Authors KK and KY were employed by Hong Kong Radiation Therapy Company Limited. Author HC was employed by Hong Kong Medical Physics Consulting Company Limited. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):777-85
pubmed: 17606334
Ann Thorac Surg. 2015 Oct;100(4):1163-5; discussion 1165-6
pubmed: 26228602
J Bronchology Interv Pulmonol. 2019 Jan;26(1):41-48
pubmed: 30179920
J Thorac Dis. 2018 Aug;10(8):4976-4984
pubmed: 30233872
Radiol Oncol. 2017 Apr 3;51(2):178-186
pubmed: 28740453
Lung Cancer. 2013 Nov;82(2):197-203
pubmed: 24051084
Respirology. 2021 May;26(5):469-476
pubmed: 33403786
Radiother Oncol. 2014 Mar;110(3):523-8
pubmed: 24560763
Radiat Oncol. 2019 Jul 11;14(1):124
pubmed: 31296231
Med Phys. 2020 Oct;47(10):e988-e1008
pubmed: 32506452
Jpn J Clin Oncol. 2017 Oct 01;47(10):969-975
pubmed: 28981731
Cardiovasc Intervent Radiol. 2010 Dec;33(6):1186-91
pubmed: 20661565
Ann Thorac Surg. 2010 Feb;89(2):368-73; discussion 373-4
pubmed: 20103300
Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):822-34
pubmed: 12095547
Cancers (Basel). 2021 Jul 20;13(14):
pubmed: 34298836
Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1228-35
pubmed: 18954717
J Surg Oncol. 2008 Sep 1;98(3):202-6
pubmed: 18618604
Med Phys. 2014 Apr;41(4):040601
pubmed: 24694118
J Thorac Oncol. 2015 Feb;10(2):324-30
pubmed: 25616177
J Appl Clin Med Phys. 2011 Apr 04;12(3):3495
pubmed: 21844863
Cureus. 2018 Oct 30;10(10):e3523
pubmed: 30648058
Am J Respir Crit Care Med. 2013 Aug 1;188(3):327-33
pubmed: 23600452
Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):438-43
pubmed: 22687196
Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):297-303
pubmed: 19362249
Radiother Oncol. 2009 Jun;91(3):296-300
pubmed: 19297048
Cancers (Basel). 2021 Sep 28;13(19):
pubmed: 34638321
Med Phys. 2011 Nov;38(11):5992-7
pubmed: 22047363
Radiat Oncol. 2019 Sep 13;14(1):167
pubmed: 31519194
Radiother Oncol. 2008 Apr;87(1):24-8
pubmed: 18334273
Chest. 2007 Sep;132(3):930-5
pubmed: 17646225